Bristol Myers Squibb & Co BMY reported better-than-expected earnings for its third quarter.
Bristol Myers Squibb said revenues came in at $10.966 billion, due to lower sales of Revlimid, partially offset by in-line products and its new product portfolio. Analysts were expecting sales of $10.965 billion. Adjusted EPS rose 1% year-over-year to $2.00, beating the consensus of $1.76.
Bristol Myers Squibb shares fell 3.8% to trade at $50.94 on Friday.
These analysts made changes to their price targets on Bristol Myers Squibb following earnings announcement.
- HSBC cut the price target on Bristol Myers Squibb from $55 to $53. HSBC analyst Rajesh Kumar upgraded the stock from Reduce to Hold.
- Barclays slashed the price target on Bristol Myers Squibb from $60 to $51. Barclays analyst Carter Gould maintained an Equal-Weight rating.
- Morgan Stanley lowered the price target on Bristol Myers Squibb from $56 to $50. Morgan Stanley analyst Terence Flynn maintained an Underweight rating.
- William Blair analyst Matt Phipps, meanwhile, downgraded Bristol-Myers from Outperform to Market Perform.
- BMO Capital analyst Evan Seigerman downgraded the stock from Outperform to Market Perform.
Also Check This Out: Top 4 Industrial Stocks That May Plunge In Q4
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.